Patent intelligence · US
US 12378277
SGLTS/DPP4 inhibitor and application thereof
SGLTS/DPP4 inhibitor and application thereof
Patent details — US 12378277
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 5, 2025
- Expiration
- Jul 31, 2045
- Claims
- 17
- CPC classes
- A61P, A61P3/00, A61P3/10
Quick answer
US 12378277 (SGLTS/DPP4 inhibitor and application thereof) is held by DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD.. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61P, A61P3/00, A61P3/10
More from DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12378277?
US 12378277 (SGLTS/DPP4 inhibitor and application thereof) is held by DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD.. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12378277?
DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 12378277 expire?
Our index shows an expiration date of Jul 31, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.